Sanofi ($SNY) is set to acquire Inhibrx ($INBX) for $30 per share in cash, a contingent value right (CVR) of $5, and 0.25 shares in a new publicly traded company. The deal includes up to $2.2 billion in aggregate value, with the new company retaining all non INBRX-101 assets of $INBX. This acquisition has prompted discussions about the potential value of Mereo BioPharma ($MREO) and its Alvelestat candidate in comparison to INBRX-101. Some analysts believe that INBX may be undervalued following the deal with SNY.
$INBX Might be missing something, but $INBX looking undervalued here, post $SNY.
$INBX interesting carve out deal for the AATD asset - .. maybe we will see more of these - buyers can pick on the things they like and take them whole and spinco the rest for the mgmt team to play a new game - .. that said, the $BHVN spinco success, imo, is far less…
$MREO and $INBX $SNY purchase of $INBX AATD Tx candidate, 101, makes it a good time to revisit 101, and its proposed “better mousetrap” to traditional augmentation approach, versus $MREO Alvelestat proposed truly unique mechanism of action, as an oral small molecule, no less:… https://t.co/6WER7XwtPu
$INBX — $SNY, $XBI $MREO $INBX sells their AATD candidate, INBRX-101, to $SNY for up to $2.2b — $30 per share in cash, $5 CVR, and .25 share in New Inhibrx. Should serve as point of comparison for potential value of $MREO Alvelestat in AATD, a candidate at similar clinical… https://t.co/xV71XOPQSx https://t.co/GjC1eDgVCA
$SNY to acquire $INBX for $30/share in cash, a CVR equal to $5, plus 0.25 shares in New Inhibrx, a new publicly traded company that retains all non INBRX-101 assets of $INBX with debt paid off plus $200m cash for aggregate value up to $2.2B. https://t.co/PHzPxhEa3m
The Undervalued Stock That Superinvestors Are Loading Up On To find out which stock superinvestors are loading up on, click here: https://t.co/B8C2ghZo1N https://t.co/Cuc5ZGVL8u